Expression of tumor pyruvate kinase M2 isoform in plasma and stool of patients with colorectal cancer or adenomatous polyps.
Blood
Colon
M2-PK enzyme, diagnosis
Malignancy
Non-invasive
Journal
BMC gastroenterology
ISSN: 1471-230X
Titre abrégé: BMC Gastroenterol
Pays: England
ID NLM: 100968547
Informations de publication
Date de publication:
29 Jul 2020
29 Jul 2020
Historique:
received:
14
10
2019
accepted:
09
07
2020
entrez:
31
7
2020
pubmed:
31
7
2020
medline:
15
5
2021
Statut:
epublish
Résumé
Tumor pyruvate kinase M2 isoform (tM2-PK), which is an isoform of PK-glycolytic enzyme and appears on the surface of cancerous proliferating cells, has been used as a diagnostic biomarker for colorectal cancer (CRC). The aim of this study was to evaluate the tM2-PK measurement test for the diagnosis of CRCs and adenomatous polyps in plasma and stool samples in an Iranian population. In this prospective study, a total of 226 stool and 178 plasma samples were received from patients referred to colonoscopy units. tM2-PK enzyme was measured using two separate ScheBo-Biotech-AG ELISA kits for stool and plasma samples. According to ROC curves, in the tumor group, at the cut-off value of 4 U/ml, the sensitivity of fecal tM2-PK test was 100% and the specificity was 68%, and in the polyp group, the sensitivity and specificity were 87 and 68%, respectively. For tumor detection in plasma specimens, a cut-off value > 25 U/ml has a sensitivity and specificity of 90.9 and 91.3%, respectively. Similarly, for polyp detection, a cut-off value > 19 U/ml has a sensitivity of 96.3% and the specificity of 85.5%. Based on our results, a cut-off range of 4.8-8 U/ml and > 8 U/ml could be used to detect polyp and tumor in stool samples, respectively. Similarly, a cut-off range of 19-25 U/ml and > 25 U/ml is recommended in plasma samples, suggesting tM2-PK test as a non-invasive assay to diagnose CRC and adenomatous polyps.
Sections du résumé
BACKGROUND
BACKGROUND
Tumor pyruvate kinase M2 isoform (tM2-PK), which is an isoform of PK-glycolytic enzyme and appears on the surface of cancerous proliferating cells, has been used as a diagnostic biomarker for colorectal cancer (CRC). The aim of this study was to evaluate the tM2-PK measurement test for the diagnosis of CRCs and adenomatous polyps in plasma and stool samples in an Iranian population.
METHODS
METHODS
In this prospective study, a total of 226 stool and 178 plasma samples were received from patients referred to colonoscopy units. tM2-PK enzyme was measured using two separate ScheBo-Biotech-AG ELISA kits for stool and plasma samples.
RESULTS
RESULTS
According to ROC curves, in the tumor group, at the cut-off value of 4 U/ml, the sensitivity of fecal tM2-PK test was 100% and the specificity was 68%, and in the polyp group, the sensitivity and specificity were 87 and 68%, respectively. For tumor detection in plasma specimens, a cut-off value > 25 U/ml has a sensitivity and specificity of 90.9 and 91.3%, respectively. Similarly, for polyp detection, a cut-off value > 19 U/ml has a sensitivity of 96.3% and the specificity of 85.5%.
CONCLUSIONS
CONCLUSIONS
Based on our results, a cut-off range of 4.8-8 U/ml and > 8 U/ml could be used to detect polyp and tumor in stool samples, respectively. Similarly, a cut-off range of 19-25 U/ml and > 25 U/ml is recommended in plasma samples, suggesting tM2-PK test as a non-invasive assay to diagnose CRC and adenomatous polyps.
Identifiants
pubmed: 32727566
doi: 10.1186/s12876-020-01377-x
pii: 10.1186/s12876-020-01377-x
pmc: PMC7388451
doi:
Substances chimiques
Biomarkers, Tumor
0
Isoenzymes
0
Pyruvate Kinase
EC 2.7.1.40
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
241Références
PLoS One. 2015 Jul 09;10(7):e0131616
pubmed: 26158845
Curr Oncol. 2017 Apr;24(2):e131-e137
pubmed: 28490936
Eur J Gastroenterol Hepatol. 2007 Mar;19(3):265-76
pubmed: 17301655
JAMA. 2000 Oct 18;284(15):1954-61
pubmed: 11035892
Br J Cancer. 2008 Jul 8;99(1):133-5
pubmed: 18542075
J Dig Dis. 2010 Jun;11(3):148-60
pubmed: 20579218
J Gastrointest Cancer. 2019 Sep;50(3):442-450
pubmed: 29626277
J Gastrointestin Liver Dis. 2016 Mar;25(1):71-7
pubmed: 27014756
Genes Genomics. 2018 Apr;40(4):423-428
pubmed: 29892846
PLoS One. 2018 Jul 19;13(7):e0200735
pubmed: 30024936
Int J Cancer. 2006 Dec 1;119(11):2651-6
pubmed: 16929517
Cancer Epidemiol Biomarkers Prev. 2007 Oct;16(10):1935-53
pubmed: 17932341
Ann Clin Lab Sci. 2016 Spring;46(2):154-60
pubmed: 27098621
Int J Colorectal Dis. 2012 Dec;27(12):1657-64
pubmed: 22696204
Clin Chim Acta. 2019 Jan;488:209-214
pubmed: 30445031
Internist (Berl). 2005 Apr;46(4):401-10
pubmed: 15723147
Anticancer Res. 2007 Jul-Aug;27(4A):1949-52
pubmed: 17649802
Acta Med Indones. 2012 Apr;44(2):94-9
pubmed: 22745138
Br J Cancer. 2004 Aug 31;91(5):980-4
pubmed: 15266315
Br J Cancer. 2007 May 7;96(9):1329-34
pubmed: 17406361